Radioactive prostate cancer drug given NHS go-ahead

A radioactive prostate cancer drug has been recommended for routine NHS use following a decision by the National Institute for Health and Care Excellence (Nice).
Radium-223 dichloride, marketed as Xofigo, could be made available for treating prostate cancer patients as early as December.
The draft guidance on the drug – which homes in on tumours that have spread to the bones and attacks them with alpha radiation – is seen by charities an “important victory” for some patients.
It is hoped that Radium-223 can be used to help those who are too unwell to undertake chemotherapy.
Read more …

Join Our Mailing List